In An Organic Compound Patents (Class 424/1.65)
  • Publication number: 20140186260
    Abstract: A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less.
    Type: Application
    Filed: December 24, 2013
    Publication date: July 3, 2014
    Applicants: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CANCER CENTER, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES
    Inventors: Yukie YOSHII, Hiroki Matsumoto, Mitsuyoshi Yoshimoto
  • Patent number: 8765096
    Abstract: The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises a diagnostic marker, and diagnosing the kidney disease state. The invention also relates to a method for treating a kidney disease state. The method comprises the steps of administering to a patient suffering from the disease state an effective amount of a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises an antigen, a cytotoxin, or a cell growth inhibitor, and eliminating the disease state.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: July 1, 2014
    Assignee: Endocyte, Inc
    Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov
  • Patent number: 8765097
    Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: July 1, 2014
    Assignees: Washington University, Vanderbilt University
    Inventors: Dennis E. Hallahan, Shimian Qu, Zhaozhong Han
  • Publication number: 20140178298
    Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 26, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Amin I. Kassis, Ravi S. Harapanhalli
  • Patent number: 8758724
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: June 24, 2014
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Publication number: 20140170066
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicants: Merck & Co., Inc., Visen Medical, Inc.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Patent number: 8753605
    Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of detecting the over-expression of epidermal growth factor receptor (EGFR) in a subject or sample, methods of diagnosing the presence of one or more angiogenesis related diseases or related biological events in a subject or sample, method of monitoring the progress of one or more angiogenesis related diseases or related biological events in a subject or sample, a 18F-FBEM-CYS-ZEGFR:1907 probe, compositions including a 18F-FBEM-CYS-ZEGFR:1907 probe, and pharmaceutical compositions including a 18F-FBEM-CYS-ZEGFR:1907 probe and the like.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: June 17, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Zhen Cheng, Sanjiv Sam Gambhir, Zheng Miao, Hongguang Liu, Gang Ren
  • Patent number: 8753889
    Abstract: Methods are disclosed for using stable isotopes of carbon and nitrogen in hair and feces to predict disease in animals such as predicting the susceptibility of dairy cows to periparturient production-related metabolic diseases (PRMDs). Other methods that are disclosed are for using stable isotopes of carbon and nitrogen in blood components, erythrocytes and plasma proteins, to predict dairy cow susceptibility to PRMDS; yet other disclosed methods are for using stable isotopes of carbon and nitrogen in hair and feces of horses as a prognostic indicator after surgical or medical correction of gastrointestinal colic. Other methods that are disclosed also include using stable isotopes of carbon and nitrogen in blood components, erythrocytes and plasma proteins, of horses as a prognostic indicator before or after surgical or medical correction of gastrointestinal colic.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: June 17, 2014
    Inventor: Beverly L. Roeder
  • Patent number: 8747808
    Abstract: A radiolabeled annexin comprising at least 2 up to 20 histidine residues at its N-terminus is disclosed. At least two of said histidine residues are adjacent or separated by no more than one other amino acid. The radiolabeled annexin is a stable complex with a radionuclide such as technetium 99m. The radiolabeled annexin can be used in a method of imaging cell death in a nucleated cell within a region of a mammalian subject in vivo.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: June 10, 2014
    Assignee: MosaMedix B.V.
    Inventors: Christiaan Peter Maria Reutelingsperger, Peter Jozef Jacobus Moonen
  • Patent number: 8747810
    Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: June 10, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: Ashfaq Mahmood, Alun G. Jones, Naengnoi Limpa-Amara, Yijie Peng, Zeynep Akgun
  • Publication number: 20140154178
    Abstract: A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample.
    Type: Application
    Filed: November 30, 2012
    Publication date: June 5, 2014
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Tiberiu Mircea Siclovan, Cristina Abucay Tan Hehir, Rong Zhang, Victoria Eugenia Cotero, Anshika Bajaj
  • Publication number: 20140154179
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: November 27, 2013
    Publication date: June 5, 2014
    Applicant: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Publication number: 20140154180
    Abstract: This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the three-dimensional structure of a co-crystal of a protofilament of an amyloid protein bound to a small molecule which is known to bind to the amyloid protein, and (b) selecting test compounds which exhibit an energy below that of the small molecule used to form the co-crystal made in a), as candidate amyloid binders.
    Type: Application
    Filed: July 16, 2012
    Publication date: June 5, 2014
    Applicant: The Regents of the University of California
    Inventors: David S. Eisenberg, Lin Jiang, Meytal Landau, Cong Liu
  • Patent number: 8741262
    Abstract: The present invention concerns a therapeutically labeled napthodianthrone or phenanthro[1,10,9,8-opqra]perylene-7,14-dione compound, which comprises a chemical element or an isotope that has an unstable nucleus and emits radiation during its decay to a stable form sufficient to destroy neighboring cells or tissues for use in a targeted radiotherapy to enhance curability of a warm-blooded animal that has been subjected to a necrosis-inducing antitumor therapy. A particular advantage of present invention is that viable rim resistant to a necrosis-inducing antitumor therapy such as vascular targeting agent (VTA) can be supplemented by one single or repeated doses of a therapeutically radiolabeled small molecule necrosis-avid chemical compound treatment to enhance the curability.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: June 3, 2014
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Yicheng Ni, Marie Van De Putte, Peter DeWitte, Alfons Verbruggen, Guy Marchal, Ziping Sun
  • Publication number: 20140134106
    Abstract: The present invention describes oxidized avidin, suitable for inhalation, for conditioning the lung affected by inoperable/diffuse diseases, enabling the targeted delivery of biotinylated therapeutic agents to it.
    Type: Application
    Filed: July 25, 2012
    Publication date: May 15, 2014
    Applicant: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
    Inventor: Rita De Santis
  • Patent number: 8709382
    Abstract: The present application discloses compositions and methods of synthesis and use of 18F- or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the bifunctional chelating agent bound to 18F- or 19F-metal complex may be conjugated to the molecule to be labeled at a reduced temperature, e.g. room temperature.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: April 29, 2014
    Assignee: Immunomedics, Inc.
    Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
  • Patent number: 8703098
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 22, 2014
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 8703942
    Abstract: The present disclosure provides inhibitors of Hsp90 and methods of making and using the same. Such compounds are useful as radioimaging ligands and for the treatment of cancer and other conditions where cell growth or maintenance depend on Hsp90 activity.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: April 22, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steve M. Larson, Peter Smith-Jones
  • Patent number: 8703095
    Abstract: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The invention also relates to a process for preparing an immunogenic composition according to which at least one vaccine antigen is mixed with an oil-in-water emulsion, wherein the oil-in-water emulsion is obtained by means of a temperature-variation phase-inversion process.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: April 22, 2014
    Assignee: Sanofi Pasteur S.A.
    Inventors: Marie-Francoise Klucker, Francois Dalencon, Patricia Probeck-Quellec
  • Patent number: 8697029
    Abstract: The present invention relates to modulated (e.g., magnetically modulated) chemical sensors. In particular, the present invention relates to particles comprising fluorescent indicator dyes and methods of using such particles. Magnetic fields and/or Brownian motion modulate an optical property of the particle to distinguish it from background signals. The present invention thus provides improved methods of detecting a wide variety of analytes in fluids, fluid samples, cells and tissues.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: April 15, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: Jeffrey Anker, Caleb Behrend, Raoul Kopelman, Brandon McNaughton
  • Patent number: 8697031
    Abstract: The invention relates to micelles that are elaborated with functionality useful for imaging and/or selectively targeting tissue, e.g., in the delivery of hydrophobic agents.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: April 15, 2014
    Assignee: Case Western Reserve University
    Inventors: Hua Ai, Jeffrey L. Duerk, Chris Flask, Jinming Gao, Jonathan S. Lewin, Xintao Shuai, Brent Weinberg
  • Patent number: 8691187
    Abstract: Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and ?-amyloid peptides are presented herein. The invention also relates to methods of imaging A? and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: April 8, 2014
    Assignee: Eli Lilly and Company
    Inventors: Anna Katrin Szardenings, Wei Zhang, Dhanalakshmi Kasi, Anjana Sinha, Umesh B. Gangadharmath, Joseph C. Walsh
  • Patent number: 8691185
    Abstract: This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s).
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 8, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: William E. Klunk, Chester A. Mathis, Jr., Yanming Wang
  • Patent number: 8691280
    Abstract: The invention provides a microsphere comprising an organic lanthanide metal complex wherein the lanthanide metal is present in an amount of more than 20 wt %, based on total microsphere. The invention further provides a suspension comprising such a microsphere. In addition, the invention relates to a method for preparing said microsphere, and the use of the microsphere(s) or suspension for treating a malignancy and/or obtaining a scanning image.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: April 8, 2014
    Assignees: UMC Utrecht Holding B.V., Stichting voor de Technische Wetenschappen
    Inventors: Johannes F. W. Nijsen, Wouter Bult, Alfred D. van het Schip
  • Patent number: 8691189
    Abstract: The present disclosure describes techniques used for colorectal cancer detection. Position and distribution of colorectal cancer tumor are detected through nuclear imaging. Alternatively, stage of colorectal cancer is identified by shading value in tumor. Thus, the present disclosure provides a safe and noninvasive clinical method for diagnosing and tracing level and distribution of colorectal cancer before and after treatment.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: April 8, 2014
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council
    Inventors: Siao-Syun Guan, Chun-Chia Cheng, Shui-Cheng Lee, Hsien-Ming Wu
  • Patent number: 8691255
    Abstract: This invention relates to a method of producing and dispensing a foam using a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 8, 2014
    Assignee: Deb Worldwide Healthcare Inc.
    Inventors: Maria Teresa Fernandez de Castro, Bruce Michael Koivisto, Francisco Munoz
  • Publication number: 20140093451
    Abstract: Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Inventor: Lawrence Richard Bernstein
  • Patent number: 8685369
    Abstract: One aspect of the invention relates to complexes of a radionuclide with various heteroaryl ligands, e.g., imidazolyl and pyridyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to imidazolyl and pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the radionuclide complexes are also described. Another aspect of the invention relates to imidazolyl and pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: April 1, 2014
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John Babich, Kevin Maresca, James Kronauge
  • Patent number: 8685371
    Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumors following cancer treatment.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 1, 2014
    Assignee: Cambridge Enterprise Limited
    Inventors: Kevin Brindle, Andre Neves, Maaike De Backer, Israt Alam
  • Patent number: 8685422
    Abstract: This invention relates to a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise a C1-4 alcohol, (>40% v/v), a silicone-based surfactant of at least 0.001% by weight for foaming to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and mosturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 1, 2014
    Assignee: Deb Worldwide Healthcare Inc.
    Inventors: Maria Teresa Fernandez de Castro, Bruce Michael Koivisto, Francisco Munoz
  • Patent number: 8685370
    Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: April 1, 2014
    Assignees: Visen Medical, Inc., Merck & Co., Inc.
    Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
  • Patent number: 8685367
    Abstract: Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: April 1, 2014
    Assignee: Rutgers, The State University of of New Jersey
    Inventors: Donald K. Brandom, Eric Schmid, Joan Zeltinger, Durgadas Bolikal, Joachim B. Kohn
  • Publication number: 20140086834
    Abstract: The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition.
    Type: Application
    Filed: May 24, 2011
    Publication date: March 27, 2014
    Applicant: UNIVERSITA' DEGLI STUDI DI BARI ''ALDO MORO''
    Inventors: Marcello Leopoldo, Enza Lacivita, Nicola Colabufo, Paola De Giorgio, Francesco Berardi, Roberto Perrone
  • Publication number: 20140086833
    Abstract: The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described.
    Type: Application
    Filed: November 29, 2013
    Publication date: March 27, 2014
    Inventor: Jeffrey P. Norenberg
  • Patent number: 8679454
    Abstract: Surface coatings including microparticles immobilized in a matrix of polymeric material on a substrate are described. The microparticles can also include an agent which can be useful for various applications, such as medical applications. This invention relates to the field of surface coatings for use in various applications. More particularly, the invention relates to surface coating useful for drug delivery, imaging and other uses of microparticles immobilized via a polymeric matrix.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: March 25, 2014
    Assignee: Surmodics, Inc.
    Inventors: Patrick E. Guire, Kristin S. Taton, John V. Wall
  • Patent number: 8679453
    Abstract: This invention includes agents and compositions having MRI, PET, CT, X-ray, SPECT or optical signals, and methods for their use in the determination of a target. In some cases, a MRI, PET, CT, X-ray, SPECT, optical or other signal produced by the agent or composition can be affected by the presence of the target. Examples of targets that can be determined by this invention include, but are not limited to zinc, copper, iron ions and other biological targets. Example of application for imaging in vivo includes the function of pancreas and other organs.
    Type: Grant
    Filed: March 28, 2010
    Date of Patent: March 25, 2014
    Assignee: Universidad de Guanajuato
    Inventor: Luis M. De Leon-Rodriguez
  • Patent number: 8679516
    Abstract: This invention relates to a “high lower alcohol content” (>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: March 25, 2014
    Assignee: Deb Worldwide Healthcare Inc.
    Inventors: Maria Teresa Fernandez de Castro, Bruce Michael Koivisto, Francisco Munoz
  • Patent number: 8679455
    Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods of making such radiodiagnostic and radiotherapeutic agents and the compounds used in such methods. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 25, 2014
    Assignee: Hammersmith Imanet Limited
    Inventors: Erik Arstad, Matthias Eberhard Glaser
  • Publication number: 20140079631
    Abstract: Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.
    Type: Application
    Filed: March 23, 2012
    Publication date: March 20, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Charles N. Serhan, Lucy V. Norling, Matthew Spite, Jesmond P. Dalli
  • Patent number: 8673266
    Abstract: The present invention relates to microspheres useful for embolization which comprises polyvinylalcohol. The present invention also relates to an injectable suspension suitable for embolization which comprises the polyvinylalcohol microspheres and a suitable liquid carrier. The present invention further relates to a method for prophylactic or therapeutic embolization which comprises administering to a mammal an injectable suspension containing the polyvinylalcohol microspheres and a suitable liquid carrier. Finally, the present invention relates to a process for producing the polyvinylalcohol microspheres.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: March 18, 2014
    Assignee: Biosphere Medical, S.A.
    Inventor: Egisto Boschetti
  • Patent number: 8673841
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia compromised lactation conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: March 18, 2014
    Assignee: Ferring B.V.
    Inventors: Sudar Alagarsamy, Robert Galyean, Kaszimierz Wisniewski, Claudio Schteingart
  • Patent number: 8668900
    Abstract: The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 99mTcO4, which carries technetium-99m. In use, a patient is administered an effective amount of the radioimaging agent by injection and then scanned with a radioimaging device. The radioimaging agent is used to image select soft tissues in the patient, such as the liver or gallbladder, the upper abdominal organs, or the like, and to detect increased choline uptake. Choline is known to accumulate in cancerous cells. Thus, the radioimaging agent is particularly effective in the detection of potentially cancerous tissues.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: March 11, 2014
    Assignee: Kuwait University
    Inventor: Fatma Jassab Faleh Marzooq Al-Saeedi
  • Publication number: 20140065067
    Abstract: Iodinated amphiphilic compound of formula (I): AG1-X—R??(I) wherein AG1 represents an unsaturated (C8-C52) aliphatic hydrocarbon chain found in fatty acids having specific location of double bonds, the chain including at least one iodine atom directly linked to a carbon atom of a non-conjugated double bond by a covalent link, the second carbon atom of the double bond bearing a halogen atom different from a iodine atom, X represents a polyethylene glycol including 1 to 50 ethylene glycol groups, R represents a hydrogen atom or a group AG2 being identical to or different from AG1, AG1, X, R and AG2 being selected so that the amphiphilic compound has a hydrophilic/lipohilic balance included between 4 and 30.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 6, 2014
    Applicant: UNIVERSITE DE STRASBOURG
    Inventors: François Hallouard, Nicolas Anton, Guy Zuber, Thierry Vandamme, André Constantinesco, Philippe Choquet
  • Publication number: 20140065066
    Abstract: The invention relates to a method of treating or diagnosing a disease state mediated by monocytes. The method utilizes a composition comprising a conjugate or complex of the general formula Ab-X wherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the disease state, the group X comprises an imaging agent.
    Type: Application
    Filed: March 11, 2013
    Publication date: March 6, 2014
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventor: PURDUE RESEARCH FOUNDATION
  • Publication number: 20140065065
    Abstract: An embodiment of the invention comprises method of imaging a target site comprising administrating ligand of Formula I complexed to 99mTc wherein R1 and R2 are independently an alkyl or cycloalkyl; R3 is and alkyl; X is CO or SO2; Y is (CH2)n, C6H4, (OCH2CH2)n (NHCH2CH2)n and (OCH2CH2CH2)n, or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: GENERAL ELECTRIC COMPANY
    Inventors: Bruce Fletcher Johnson, Randall Lee Carter, Michael James Rishel, Mark Christopher Patrick Darey, Tao Wu, Yang Yang, John Fitzmaurice Valliant, Karin Ann Stephenson
  • Patent number: 8663602
    Abstract: The invention enables high-throughput screening of compounds in living systems to detect unanticipated or unintended biological actions. The invention also allows for screening, detection, and confirmation of new indications for approved drugs. Screening and detection of toxic effects of compounds also can be achieved by using the methods of the invention. The methods comprise administering isotope-labeled substrates to a living system so that the label is incorporated into molecules in a manner that reveals flux rates through metabolic pathways thought to be involved in a disease. Comparisons between living systems exposed to compounds and living systems not so exposed reveals the effects of the compounds on the flux rates through the metabolic pathways. Combinations or mixtures of compounds can be systematically screened to detect unanticipated or unintended biological actions, including synergistic actions, in the same manner.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: March 4, 2014
    Assignee: The Regents of the University of California
    Inventor: Marc K. Hellerstein
  • Patent number: 8663603
    Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: March 4, 2014
    Assignees: Bracco Suisse SA, Dyax Corp.
    Inventors: Christophe Arbogast, Philippe Bussat, Hong Fan, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Feng Yan, Aaron K. Sato, Sharon Michele Walker, Daniel T. Dransfield
  • Publication number: 20140056809
    Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 27, 2014
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventor: Purdue Research Foundation
  • Patent number: 8658129
    Abstract: The present invention relates to agents capable of binding to myelin basic protein in a subject. Also provided are methods for the detection of myelin-associated neuropathy comprising identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, administering to a subject an agent that binds specifically to myelin basic protein, and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: February 25, 2014
    Assignee: General Electric Company
    Inventors: Rong Zhang, Tiberiu Mircea Siclovan, Cristina Abucay Tan Hehir, Victoria Eugenia Cotero, Bruce Fletcher Johnson
  • Patent number: 8658132
    Abstract: A method for producing a radioactive diagnostic imaging agent containing a radioactive 18 fluorine-labeled organic compound represented by the following formula (1): as an effective ingredient in which radiolysis of the effective ingredient is inhibited, involves providing a solution containing the radioactive 18fluorine-labeled organic compound represented by the above formula (1), adding an acid to the solution obtained in the first step in an amount sufficient for the solution to be kept within a pH of 2.0-5.9 in the following third step, and diluting the solution obtained in the second step in order to adjust the solution to a desired radioactive concentration within a pH of 2.0-5.9.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: February 25, 2014
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Daisaku Nakamura, Soichi Nakamura, Masahito Toyama, Akio Hayashi